Sponsored For
Beginners Choice

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Heat Biologics, Inc is a biotechnology business based in the US. Heat Biologics shares (HTBX) are listed on the NASDAQ and all prices are listed in US Dollars. Heat Biologics employs 36 staff and has a trailing 12-month revenue of around USD$4.3 million.
Since the stock market crash in March caused by coronavirus, Heat Biologics's share price has had significant positive movement.
Its last market close was USD$1.18, which is 77.33% up on its pre-crash value of USD$0.2675 and 505.13% up on the lowest point reached during the March crash when the shares fell as low as USD$0.195.
If you had bought USD$1,000 worth of Heat Biologics shares at the start of February 2020, those shares would have been worth USD$2,635.32 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$4,997.88.
Latest market close | USD$1.18 |
---|---|
52-week range | USD$1.365 - USD$30.1 |
50-day moving average | USD$6.2167 |
200-day moving average | USD$9.0649 |
Wall St. target price | USD$31.25 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.654 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the last close of $1.18
1 week (2021-01-15) | -81.39% |
---|---|
1 month (2020-12-23) | -79.44% |
3 months (2020-10-23) | -0.84% |
6 months (2020-07-23) | -56.93% |
1 year (2020-01-23) | 304.11% |
---|---|
2 years (2019-01-23) | -11.28% |
3 years (2018-01-23) | -59.73% |
5 years (2016-01-22) | -54.09% |
Revenue TTM | USD$4.3 million |
---|---|
Gross profit TTM | USD$-9,964,500 |
Return on assets TTM | -17.49% |
Return on equity TTM | -33.73% |
Profit margin | 0% |
Book value | $5.418 |
Market capitalisation | USD$161.9 million |
TTM: trailing 12 months
There are currently 2.3 million Heat Biologics shares held short by investors – that's known as Heat Biologics's "short interest". This figure is 7.1% up from 2.2 million last month.
There are a few different ways that this level of interest in shorting Heat Biologics shares can be evaluated.
Heat Biologics's "short interest ratio" (SIR) is the quantity of Heat Biologics shares currently shorted divided by the average quantity of Heat Biologics shares traded daily (recently around 1.4 million). Heat Biologics's SIR currently stands at 1.66. In other words for every 100,000 Heat Biologics shares traded daily on the market, roughly 1660 shares are currently held short.
However Heat Biologics's short interest can also be evaluated against the total number of Heat Biologics shares, or, against the total number of tradable Heat Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heat Biologics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Heat Biologics shares in existence, roughly 100 shares are currently held short) or 0.1055% of the tradable shares (for every 100,000 tradable Heat Biologics shares, roughly 106 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Heat Biologics.
This vacation-rental giant has finally gone public. Learn how to invest in Airbnb in Ireland.
Steps to owning and managing Vaxart shares from Ireland.
Steps to owning and managing Takeda Pharmaceutical shares from Ireland.
Steps to owning and managing Sinovac Biotech Ltd shares from Ireland.
Steps to owning and managing Mesoblast shares from Ireland.
Steps to owning and managing Inovio Pharmaceuticals shares from Ireland.
Steps to owning and managing CytoDyn shares from Ireland.
Steps to owning and managing Cynata Therapeutics shares from Ireland.
Steps to owning and managing BioNTech shares from Ireland.
Steps to owning and managing Atomo Diagnostics shares from Ireland.